Second-line treatment with CDK4/6 inhibition was associated with fewer toxicities and drug costs than frontline CDK4/6 inhibitor treatment—although progression-free survival and overall survival outcomes were similar.
The rates of treatment discontinuation were higher with enzalutamide and apalutamide than with darolutamide for patients with non-metastatic castration resistant prostate cancer.
Frontline chemoimmunotherapy was associated with improved median overall survival, compared with chemotherapy alone, in patients with advanced non–small cell lung cancer.
Maintenance bevacizumab plus durvalumab and olaparib improved progression-free survival in patients with HRD-negative advanced ovarian cancer.
The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.
Patients with relapsed/refractory multiple myeloma treated with elranatamab following any prior BCMA-directed therapy achieved an overall response rate of 46%.
Omitting radiotherapy did not compromise overall survival rates for patients with primary mediastinal B-cell lymphoma.
Patients with ESR1 mutations who received 12 months or more of prior treatment with a CDK4/6 inhibitor achieved a median progression free survival of 8.61 months with elacestrant compared with 1.91 months for those given standard therapy.
Patients with HER2-positive, metastatic colorectal cancer derived clinical benefit from a 5.4 mg/kg dose of trastuzumab deruxtecan.
Enfortumab vedotin plus pembrolizumab elicited durable responses in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.
According to investigators, digitized cognitive behavioral stress management may help clinicians offer more comprehensive cancer care.
Sacituzumab govitecan improved overall survival vs treatment of physician’s choice in pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.
Ciltacabtagene autoleucel improved progression-free survival vs pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with lenalidomide-refractory multiple myeloma.
Adjuvant mRNA-4157, in combination with pembrolizumab, improved recurrence-free survival, and distant metastasis-free survival, for patients with high-risk melanoma.
Phase 2 findings show that adding a tyrosine kinase inhibitor to dual immunotherapy curbed disease progression in patients with metastatic soft tissue sarcoma.
Numerical, but not statistically significant, improvements in survival were observed in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous non–small cell lung cancer who received pembrolizumab to pemetrexed and platinum-based chemotherapy.
Sintilimab plus chemoradiotherapy was associated with better event-free survival rates in locally advanced nasopharyngeal carcinoma than chemoradiotherapy alone.
A 5-year analysis of the phase 3 KEYNOTE-426 trial showed continued benefit with pembrolizumab plus axitinib for patients with advanced treatment-naïve clear cell renal cell carcinoma.
Axicabtagene ciloleucel delivered superior overall survival compared with standard of care in patients with early relapsed or refractory large B-cell lymphoma.
Patients with pretreated FGFR2/3-altered metastatic urothelial cancer derived a significant survival benefit with erdafitinib.
In the phase 2 DESTINY-PanTumor02 trial, trastuzumab deruxtecan elicited clinical activity across a range of HER2 expressing solid tumors.
Nirogacestat significantly reduced pain scores for patients with desmoid tumors.
Vorasidenib reduced the risk of progression or death by 61% compared with placebo for patients with grade 2 IDH-mutant glioma.
An analysis of patient-reported outcomes in the phase 3 RUBY trial supports dostarlimab use in patients with primary advanced or recurrent endometrial cancer.
Mirvetuximab soravtansine demonstrated an overall survival benefit in FRα-high, platinum-resistant ovarian cancer vs investigator's choice chemotherapy.
Patients with advanced-stage Hodgkin lymphoma who received nivolumab plus AVD experienced a 1-year estimated progression-free survival rate of 94% meeting the primary end point of the phase 3 SWOG S1826 trial.
Adjuvant osimertinib reduced the risk of death by 51% compared with placebo for patients with EGFR-mutated, stage IB, II, or IIIA non–small cell lung cancer.
Preoperative FOLFOX demonstrated noninferior efficacy outcomes vs preoperative chemoradiation in locally advanced rectal cancer.
Pembrolizumab before and after resection improves event-free survival outcomes for patients with early-stage NSCLC, according to findings from KEYNOTE-671.
Treatment with imetelstat elicited statistically significant and clinically meaningful improvements in transfusion independence among patients with lower-risk myelodysplastic syndrome.
